LOAMU
LPCN icon

Lombard Odier Asset Management (USA)’s Lipocine LPCN Stock Holding History

Lombard Odier Asset Management (USA)’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-5,665
Closed -$293K – 263
2016
Q2 		$293K Buy
+5,665
New +$877K 0.04% 200

Other funds holding LPCN

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Lombard Odier Asset Management (USA)'s LPCN Position: Q2 2016 in Review

Lombard Odier Asset Management (USA) sold out of Lipocine (LPCN) in Q2 2016, closing a stake of 6,984 shares — an estimated $1.08M sold.

Lombard Odier Asset Management (USA) first reported a position in LPCN in Q2 2014 and held it in 8 quarters. The position peaked at $4.43M in Q2 2015. 54 funds tracked by Wall St. Rank hold LPCN as of Q2 2016.

  • Lombard Odier Asset Management (USA) reported no remaining Lipocine position as of Q2 2016 after selling out during the quarter.
  • Lombard Odier Asset Management (USA) sold 6,984 Lipocine shares in Q2 2016, an estimated $1.08M.
  • Lombard Odier Asset Management (USA) first reported a position in Lipocine in Q2 2014 and held it in 8 quarters.
  • Lombard Odier Asset Management (USA)'s Lipocine position peaked at $4.43M in Q2 2015.
  • 54 funds tracked by Wall St. Rank held Lipocine as of Q2 2016.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q2 2016, filed 15 Aug 2016.